Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 4

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 94Leukemia 18Leukemia, Myeloid, Chronic-Phase 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Blast Crisis 8Myeloproliferative Disorders 4Leukemia, Myeloid 4Bone Marrow Diseases 4Recurrence 3Philadelphia Chromosome 3Leukemia, Myeloid, Accelerated Phase 3Hematologic Diseases 3Bronchiolitis Obliterans Syndrome 3Hematologic Neoplasms 2Piebaldism 1Neoplastic Processes 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm, Residual 1Mastocytosis, Systemic 1Leukemia, Myeloid, Acute 1Hypereosinophilic Syndrome 1Gastrointestinal Stromal Tumors 1

Interventions

Imatinib Mesylate 9fludarabine 5Whole-Body Irradiation 5Tacrolimus 5Mycophenolic Acid 5Cyclophosphamide 5Busulfan 5ponatinib 4nilotinib 4fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Cytarabine 3Bone Marrow Transplantation 3venetoclax 2thymoglobulin 2asciminib 2Sirolimus 2Patient Reported Outcome Measures 2Methotrexate 2Mesna 2Melphalan 2Dasatinib 2Behavior Therapy 2Azacitidine 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2zileuton 1spartalizumab 1sabatolimab 1nicotinamide-beta-riboside 1methanesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Leukemia, Myeloid × nilotinib × Myeloid × Clear all
NCT03578367 2026-04-21

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Novartis

Phase 2 Completed
104 enrolled 33 charts
MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02627677 2021-11-26

OPTIC-2L

Takeda

Phase 3 Terminated
44 enrolled 22 charts
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00471497 2020-11-18

ENESTnd

Novartis

Phase 3 Completed
846 enrolled 33 charts
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

NCT00519090 2011-11-07

ENEST

Novartis

Phase 3 Terminated
6 enrolled 6 charts
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡